Literature DB >> 3159350

Suppressor-cell functions in bullous pemphigoid.

A R Ahmed.   

Abstract

T Cells from 14 patients in the active stage of bullous pemphigoid and 10 patients in the inactive stage of the disease were studied with Leu-1, Leu-2, and Leu-3 monoclonal antibodies. The proportions of total T cells and T cells expressing either helper or suppressor phenotype in the peripheral blood of patients were not significantly different to those observed in normal subjects. In 15 patients with active disease, immunoregulatory mechanisms were functionally studied using an assay measuring the amount of total IgG synthesized in vitro. Peripheral-blood leukocytes were separated into T- and B-cell fractions, and cultured in various combinations. In ten experiments, prior to culturing with B cells, the T cells were irradiated to remove their suppressor function. No statistically significant differences were observed in the amount of total IgG synthesized by B cells obtained from patients and normal subjects when they were cultured with untreated T cells or irradiated T cells obtained from patients or normal controls. These results indicate that, in patients with bullous pemphigoid, there is no loss of suppressor-cell function or increased helper-cell function as assessed by measuring the total IgG synthesized. Therefore, the immunoregulatory defect, if present, is a highly specific one and can only be studied using antigen-specific assays.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3159350     DOI: 10.1007/bf00509086

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  33 in total

1.  Immunoregulation in humans: control of antitetanus toxoid antibody production after booster immunization.

Authors:  R H Stevens; A Saxon
Journal:  J Clin Invest       Date:  1978-12       Impact factor: 14.808

Review 2.  Cooperating and controlling functions of thymus-derived lymphocytes in relation to autoimmunity.

Authors:  A C Allison; A M Denman; R D Barnes
Journal:  Lancet       Date:  1971-07-17       Impact factor: 79.321

3.  Coexistence of helper and suppressor activities in carrier-primed spleen cells.

Authors:  E L Chan; C Henry
Journal:  J Immunol       Date:  1976-10       Impact factor: 5.422

4.  Characteristics of anti-T-cell antibodies in systemic lupus erythematosus: evidence for selective reactivity with normal suppressor cells defined by monoclonal antibodies.

Authors:  C Morimoto; E L Reinherz; T Abe; M Homma; S F Schlossman
Journal:  Clin Immunol Immunopathol       Date:  1980-08

5.  Abnormal regulation of in vitro IgG production in multiple sclerosis.

Authors:  R E Kelly; G W Ellison; L W Myers; V Goymerac; S B Larrick; C C Kelley
Journal:  Ann Neurol       Date:  1981-03       Impact factor: 10.422

6.  The role of suppressor cells in the pathogenesis of common variable hypogammaglobulinemia and the immunodeficiency associated with myeloma.

Authors:  T A Waldmann; S Broder; R Krakauer; R P MacDermott; M Durm; C Goldman; B Meade
Journal:  Fed Proc       Date:  1976-07

7.  Abnormalities of immunoregulatory T cells in disorders of immune function.

Authors:  E L Reinherz; A Rubinstein; R S Geha; A J Strelkauskas; F S Rosen; S F Schlossman
Journal:  N Engl J Med       Date:  1979-11-08       Impact factor: 91.245

8.  Loss of suppressor T cells in active multiple sclerosis. Analysis with monoclonal antibodies.

Authors:  E L Reinherz; H L Weiner; S L Hauser; J A Cohen; J A Distaso; S F Schlossman
Journal:  N Engl J Med       Date:  1980-07-17       Impact factor: 91.245

9.  Alterations in immunoregulatory T cell subsets in active systemic lupus erythematosus.

Authors:  C Morimoto; E L Reinherz; S F Schlossman; P H Schur; J A Mills; A D Steinberg
Journal:  J Clin Invest       Date:  1980-11       Impact factor: 14.808

10.  Immunologic classification of lymphocytic leukemias based on monoclonal antibody-defined cell surface antigens.

Authors:  R W Schroff; K A Foon; R J Billing; J L Fahey
Journal:  Blood       Date:  1982-02       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.